Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

 

The SENSCIS Trial: Exciting News for Scleroderma-Associated ILD

New Research on Therapies for Patients with Pulmonary Fibrosis


Spring 2019 — What are the Most Exciting Things Happening in Pulmonary Disease?

New Tools to Improve the Diagnosis of IPF vs Other ILDs


Biomarkers in IPF and Other ILDs

Connective Tissue Disease-Related ILD is Now in the Limelight


Patient-Centered Outcomes for Patients with IPF: Activity Monitoring

The Impact of Anticoagulation Use on IPF Patient Outcomes: A Warning About Warfarin


Which Patients with IPF Should be on Antifibrotics? The Value of Shared Decision Making

Dyspnea Assessment in Patients with IPF